

IDS #10

SHEET 1 OF 3

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
NIH174.001C1APPLICATION NO.
09/991,721INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
McCart, et al.FILING DATE
November 13, 2001

GROUP

1636 INTER 1600/2900

RECEIVED

JUL 18 2002

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
DS	1. ✓	WO 94/16716 ✓	8/4/94	PCT				
DS	2. ✓	WO 92/15672 ✓	9/17/92	PCT				
DS	3. ✓	0 443 335 ✓	8/28/91	European Patent Office				

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
DS	4. ✓	Advani, S. J., et al. (1999) Replication-competent, Nonneuroinvasive Genetically Engineered Herpes Virus Is Highly Effective in the Treatment of Therapy-resistant Experimental Human Tumors. Cancer Res. 59:2055-2058.
DS	5. ✓	Beer, S. J., et al. (1998) Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo. Gene Ther. 5:740-746.
DS	6. ✓	Buller, R. M. L., et al. (1988) Deletion of the Vaccinia Virus Growth Factor Gene Reduces Virus Virulence. J. Virol. 62(3):866-874.
DS	7. ✓	Buller, R. M. L., et al. (1988) Cell Proliferative Response to Vaccinia Virus Is Mediated by VGF. Virology 164:182-192.
DS	8. ✓	Buller, R. M., et al. (1985) Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 317:813-815.
DS	9. ✓	Carroll, M. W. and Moss, B. (1997) Poxviruses as expression vectors. Curr. Opin. Biotechnol. 8:573-577.
DS	10. ✓	Chakrabarti, S., et al. (1997) Compact, Synthetic, Vaccinia Virus Early/Late Promoter for Protein Expression. BioTechniques 23:1094-1097.
DS	11. ✓	Chase, M., et al. (1998) An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat. Biotech. 16:444-448.
DS	12. ✓	Chillon, M., et al. (1998) Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro. Gene Ther. 5:995-1002.
DS	13. ✓	Davison, A. J. and Moss, B. (1989) Structure of Vaccinia Virus Late Promoters. J. Mol. Biol. 210:771-784.
DS	14. ✓	Davison, A. J. and Moss, B. (1989) Structure of Vaccinia Virus Early Promoters. J. Mol. Biol. 210:749-769.
DS	15. ✓	Dmitriev, I., et al. (1998) An Adenovirus Vector with Genetically Modified Fibers Demonstrates Expanded Tropism via Utilization of a Coxsackievirus and Adenovirus Receptor-Independent Cell Entry Mechanism. J. Virol. 72(12):9706-9713, 1998
DS	16. ✓	Flexner, C., et al. (1990) Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2. Vaccine 8:17-21.
DS	17. ✓	Galmiche, M. C., et al. (1997) Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumour cell targeting. J. Gen. Virol. 78:3019-3027.
DS	18. ✓	Gnant, M. F. X., et al. (1999) Systemic Administration of a Recombinant Vaccinia Virus Expressing the Cytosine Deaminase Gene and Subsequent Treatment with 5-Fluorocytosine Leads to Tumor-specific Gen Expression and Prolongation of Survival in Mice. Cancer Res. 59:3396-3403.

EXAMINER

DATE CONSIDERED

5/8/03

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (SEE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. NIH174.001C1	APPLICATION NO. 09/991,721
	APPLICANT McCart, et al.	
	FILING DATE November 13, 2001	GROUP 1636

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
DS	19. Gnant, M. F. X., et al. (1999) Regional Versus Systemic Delivery of Recombinant Vaccinia Virus as Suicide Gene Therapy for Murine Liver Metastases. <i>Ann. Surg.</i> 230(3):352-361.
DS	20. Goede, V., et al. (1998) Analysis of Blood Vessel Maturation Processes during Cyclic Ovarian Angiogenesis. <i>Lab. Invest.</i> 78(11):1385-1394.
DS	21. Gurvich, E. B. and Vilesova, I. S. (1983) Vaccinia Virus in Postvaccinal Encephalitis. <i>Acta. Virol.</i> 27:154-159.
DS	22. Heise, C., et al. (1997) ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. <i>Nat. Med.</i> 3(6):639-645.
DS	23. Hodge, J. W., et al. (1994) Induction of Antitumor Immunity by Recombinant Vaccinia Viruses Expressing B7-1 or B7-2 Costimulatory Molecules. <i>Cancer Res.</i> 54:5552-5555.
DS	24. Kantor, J., et al. (1992) Immunogenicity and Safety of a Recombinant Vaccinia Virus Vaccine Expressing the Carcinoembryonic Antigen Gene in a Nonhuman Primate. <i>Cancer Res.</i> 52:6917-6925.
DS	25. Kaplan, E. L. and Meier, P. (1958) Nonparametric Estimation From Incomplete Observations. <i>Am. Stat. Assoc. J.</i> 53:457-481.
DS	26. Karupiah, G., et al. (1990) Vaccinia virus-mediated damage of murine ovaries and protection by virus-expressed interleukin-2. <i>Immunol. Cell Biol.</i> 68:325-333.
DS	27. Keane, J. T., et al. (1983) Progressive Vaccinia Associated With Combined Variable Immunodeficiency. <i>Arch. Dermatol.</i> 119:404-408.
DS	28. Kim, C. J., et al. (1998) Use of Recombinant Poxviruses to Stimulate Anti-Melanoma T Cell Reactivity. <i>Ann. Surg. Oncol.</i> 5(1):64-76.
DS	29. Kim, D. H., and McCormick, F. (1996) Replicating viruses as selective cancer therapeutics. <i>Mol. Med. Today</i> 2:519-527.
DS	30. Kohn, S., et al. (1992) Pathways of Macromolecular Tracer Transport Across Venules and Small Veins. <i>Lab. Invest.</i> 67(5):596-607.
DS	31. Lane, J. M. and Millar, J. D. (1971) Risks of Smallpox Vaccination Complications in the United States. <i>Am. J. Epidemiol.</i> 93(4):238-240.
DS	32. Mantel, N. (1966) Evaluation of Survival Data and Two New Rank Order Statistics Arising in its Consideration. <i>Cancer Chemother. Repts.</i> 50(3):163-170.
DS	33. Martuza, R. L., et al. (1991) Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant. <i>Science</i> 252:854-856, 1991
DS	34. Mastrangelo, M. J., et al. (2000) Intralesional Vaccinia/GM-CSF Recombinant Virus in the Treatment of Metastatic Melanoma. <i>Adv. Exp. Med. Biol.</i> 465:391-400.
DS	35. Mastrangelo, M. J., et al. (1998) Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. <i>Cancer Gene Ther.</i> 6(5):409-422.
DS	36. McAneny, D., et al. (1996) Results of a Phase I Trial of a Recombinant Vaccinia Virus That Expresses Carcinoembryonic Antigen in Patients with Advanced Colorectal Cancer. <i>Ann. Surg. Oncol.</i> 3(5):495-500.
DS	37. McCart, J. A., et al. (2001) Systemic Cancer therapy with a Tumor-selective Vaccinia Virus Mutant Lacking Thymidine Kinase and Vaccinia Growth Factor Genes. <i>Cancer Res.</i> 61:8751-8757.
DS	38. McCart, J. A., et al. (2000) Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. <i>Gene Ther.</i> 7:1217-1223.
DS	39. Meko, J. B., et al. (1995) High Cytokine Production and Effective Antitumor Activity of a Recombinant Vaccinia Virus Encoding Murine Interleukin 12. <i>Cancer Res.</i> 55:4765-4770.
DS	40. Moss, B. (1996) Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. <i>PNAS USA</i> 93:11341-11348.
DS	41. Mukherjee, S., et al. (2000) Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation. <i>Cancer Gene Ther.</i> 7(5):663-670.
DS	42. O'Reilly, M. S., et al. (1997) Endostatin: an Endogenous Inhibitor of Angiogenesis and Tumor Growth. <i>Cell</i> 88:277-285.
DS	43. Overwijk, W., et al. (1999) Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4+ T lymphocytes. <i>PNAS USA</i> 96:2982-2987.
DS	44. Palumbo, G. J., et al. (1998) A Replication Competent Recombinant Vaccinia Vector Expressing HSV-TK for the Treatment of Tumors in Vivo. <i>Am. Soc. Gene Ther.</i> 1:169a.

EXAMINER	DATE CONSIDERED
DS	5/8/03

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
NIH174.001C1APPLICATION NO.
09/991,721INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
McCart, et al.FILING DATE
November 13, 2001

GROUP

4642 1136

RECEIVED

JUL 18 2002

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ET	TECH CENTER 101
DS	45. Park, B. J., et al. (1999) Augmentation of Melanoma-Specific Gene Expression Using a Tandem Melanocyte-Specific Enhancer Results in Increased Cytotoxicity of the Purine Nucleoside Phosphorylase Gene in Melanoma. Hum. Gene Ther. 10:889-898.	
DS	46. Parr, M. J., et al. (1997) Tumor-selective transgene expression <i>in vivo</i> mediated by an E2F-responsive adenoviral vector. Nat. Med. 3(10):1145-1149.	
DS	47. Peplinski, G. R., et al. (1998) Vaccinia Virus for Human Gene Therapy. Surg. Oncol. Clin. N. Am. 7(3):575-588.	
DS	48. Peplinski, G. R., et al. (1995) In vivo gene therapy of a murine pancreas tumor with recombinant vaccinia virus encoding human interleukin-1 beta. Surgery 118(2):185-191.	
DS	49. Puhlmann, M., et al. (2000) Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther. 7(1):66-73.	
DS	50. Puhlmann, M., et al. (1999) Thymidine Kinase-Deleted Vaccinia Virus Expressing Purine Nucleoside Phosphorylase as a Vector for Tumor-Directed Gene Therapy. Hum. Gene Ther. 10:649-657.	
DS	51. Qin, H. and Chatterjee, S. K. (1996) Cancer Gene Therapy Using Tumor Cells Infected with Recombinant Vaccinia Virus Expressing GM-CSF. Hum. Gene Ther. 7:1853-1860.	
DS	52. Ramshaw, I. A., et al. (1987) Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature 329:545-546.	
DS	53. Reynolds, L. P., et al. (2000) Angiogenesis in the Corpus Luteum. Endocrine. 12(1):1-9.	
DS	54. Robinson, M. J., et al. (1977) A Fatal Case of Progressive Vaccinia - Clinical and Pathological Studies. Aust. Paediat. J. 13:125-130.	
DS	55. Roper, R. L. and Moss, B. (1999) Envelope Formation Is Blocked by Mutation of a Sequence Related to the HKD Phospholipid Metabolism Motif in the Vaccinia Virus F13L Protein. J. Virol. 73(2):1108-1117.	
DS	56. Rosenberg, S. A., et al. (1999) Human Gene Marker/Therapy Clinical Protocols. Hum. Gene Ther. 10:3067-3123.	
DS	57. Siders, W. M., et al. (1996) Transcriptional Targeting of Recombinant Adenoviruses to Human and Murine Melanoma Cells. Cancer Research 56:5638-5646.	
DS	58. Smith, G. L. and Moss, B. (1983) Infectious poxvirus vectors have capacity for at least 25000 base pairs of foreign DNA. Gene 25:21-28.	
DS	59. Turkel, S. B. and Overturf, G. D. (1977) Vaccinia Necrosum Complicating Immunoblastic Sarcoma. Cancer 40:226-233.	
DS	60. Walker, J. R., et al. (1999) Local and Systemic Therapy of Human Prostate Adenocarcinoma with the Conditionally Replicating Herpes Simplex Virus Vector G207. Hum. Gene Ther. 10:2237-2243.	
DS	61. Wildner, O., et al. (1999) Therapy of Colon Cancer with Oncolytic Adenovirus Is Enhanced by the Addition of Herpes Simplex Virus-thymidine kinase. Cancer Res. 59:410-413.	
DS	62. International Search Report from Application No. PCT/US00/14679 dated 9/11/00.	

O:\DOCS\MXG\MXG-1402.DOC:vb
062402

EXAMINER DS	DATE CONSIDERED 5/8/03
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	